Perspective Therapeutics (NYSEAMERICAN:CATX) Posts Earnings Results, Beats Expectations By $0.04 EPS

Perspective Therapeutics (NYSEAMERICAN:CATX) released its quarterly earnings data on Monday. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04, FiscalAI reports. The business had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.16 million. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%.

Perspective Therapeutics Price Performance

Shares of NYSEAMERICAN CATX opened at $3.88 on Tuesday. Perspective Therapeutics has a 12-month low of $1.96 and a 12-month high of $6.16. The company has a current ratio of 5.17, a quick ratio of 5.17 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average price of $4.50 and a 200 day moving average price of $3.59.

Hedge Funds Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CATX. Opaleye Management Inc. purchased a new position in Perspective Therapeutics in the 4th quarter valued at about $3,257,000. Patient Square Capital LP boosted its position in Perspective Therapeutics by 224.3% in the 4th quarter. Patient Square Capital LP now owns 1,132,815 shares of the company’s stock valued at $3,115,000 after buying an additional 783,492 shares during the last quarter. Bank of America Corp DE boosted its position in Perspective Therapeutics by 139.9% in the 3rd quarter. Bank of America Corp DE now owns 785,823 shares of the company’s stock valued at $2,695,000 after buying an additional 458,323 shares during the last quarter. Marshall Wace LLP purchased a new position in Perspective Therapeutics in the 4th quarter valued at about $1,119,000. Finally, JPMorgan Chase & Co. boosted its position in Perspective Therapeutics by 118.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock valued at $2,573,000 after buying an additional 405,612 shares during the last quarter. 54.66% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. B. Riley Financial upped their price objective on Perspective Therapeutics from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, March 18th. BTIG Research reiterated a “buy” rating and issued a $14.00 price target on shares of Perspective Therapeutics in a report on Tuesday, March 17th. UBS Group increased their price target on Perspective Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, March 18th. Piper Sandler initiated coverage on Perspective Therapeutics in a report on Thursday, February 19th. They issued an “overweight” rating and a $16.00 price target for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a report on Tuesday, May 5th. One equities research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $12.63.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.